Skip NavigationSkip to Content

Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma

  1. Author:
    Brown, E. E.
    Whitby, D.
    Vitale, F.
    Marshall, V.
    Mbisa, G.
    Gamache, C.
    Lauria, C.
    Alberg, A. J.
    Serraino, D.
    Cordiali-Fei, P.
    Messina, A.
    Goedert, J. J.
  2. Author Address

    Univ Alabama, Dept Epidemiol, Birmingham, AL 35294 USA. NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, Rockville, MD USA. Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. NCI, SAIC Frederick, Viral Epidemiol Sect, AIDS Vaccine Program, Frederick, MD 21701 USA. Univ Palermo, Dipartimento Igiene & Microbiol Giuseppe Allessan, Palermo, Italy. Sez Ragusa, Lega Italiana Lotta Tumori, Ragusa, Italy. IRCCS, Ist Nazl Tumori Ctr Riferimento Oncol, SDC Epidemiol & Biostat, Aviano, Italy. Inst Ospitaliero San Gallicano, Clin Lab, Rome, Italy. Univ Catania, Dipartimento Sci Biomed, Catania, Italy.;Brown, EE, Univ Alabama, Dept Epidemiol, RPHB 220,1530 3rd Ave S, Birmingham, AL 35294 USA.;elbrown@uab.edu
    1. Year: 2006
    2. Date: Nov
  1. Journal: Cancer
    1. 107
    2. 9
    3. Pages: 2282-2290
  2. Type of Article: Article
  3. ISSN: 0008-543X
  1. Abstract:

    BACKGROUND. Classic Kaposi sarcoma (CKS) is an inflammatory-mediated neoplasm that develops in the presence of KS-associated herpesvirus (KSHV) and immune perturbation. In the current study, the authors compared CKS cases with age-matched and sex-matched KSHV-seropositive controls without human immunodeficiency virus-1 infection and markers of viral control, blood Counts, CD4-positive and CD8-positive lymphocytes, and serum beta-2-microglobulin and neopterin levels. METHODS. Viral loads were detected using real-time amplification of the KSHV-K6 and EBV-pol genes, anti-K8.1 (lytic) titers were detected by enzyme-linked immunoadsorbent assay, and antilatent nuclear antigen (LANA) titers were detected using immunofluorescence. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using logistic regression adjusted for sex, age, and study site. RESULTS. Peripheral blood mononuclear cells (PBMC) KSHV DNA detection (P <= .0001) and high KSHV lytic (> 1:1745; P <= .0001) and latent (> 1:102,400; P = .03) antibody titers were found to be positively associated with CKS risk. Antibody titers were higher in cases with lesions compared with cases without lesions (P <= .05). The detection of Epstein-Barr virus (EBV) DNA in PBMCs was not found to be associated with CKS (P = .95). Independent of PBMC KSHV DNA, CKS risk was found to be positively associated with reduced hematocrit (< 37.4%; P = .03), hemoglobin (< 12g/dL; P = .04), and lymphocytes (< 1000 cells/mu L; P = .004), including CD4-positive (+) cells (< 457 cells/mu L; P = .07) and CD8+ cells (< 213cells/mu L; P = .04), and with increased monocytes (>= 638 cells/mu L; P = .009). Nonsignificant elevations of beta-2-microglobulin and neopterin were observed among cases regardless of disease burden (P >= .08). In a multivariate model, the CKS risk was found to be associated with PBMC KSHV DNA (OR of 2.7; 95% CI, 1.4-5.3), a high KSHV lytic antibody titer (OR of 3.7; 95% CI, 1.9-7.4), and low lymphocytes, particularly among those patients age < 70 years (OR of 8.0; 95% CI, 2.7-23.7). CONCLUSIONS. The findings of the current study appear to corroborate the specificity of KSHV and highlight the hematologic and immunologic correlates involved in the pathogenesis of CKS.

    See More

External Sources

  1. DOI: 10.1002/cncr.22236
  2. WOS: 000241777300023

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel